Clinical trial NCT05924685: PREPARE-iVAC Trial
Official title: Prospective Randomized Trial of Everolimus Replacing MMF/MP Acid by the RECOVAC Consortium to Increase VACcine Response in Kidney Transplant Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: COVID-19 Vaccines
Varicella Zoster Vaccine
Vaccine Response
Immunosuppression
Keywords: Kidney Transplant Recipients
COVID-19 vaccines
Everolimus
Mycophenolate Mofetil
Varicella Zoster Vaccine
Lead sponsor: University Medical Center Groningen
Sponsor class: OTHER
Collaborators: name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
name: Radboud University Medical Center
name: Erasmus Medical Center
name: UMC Utrecht
name: Leiden University Medical Center
name: Maastricht University Medical Center
name: ZonMw: The Netherlands Organisation for Health Research and Development
name: Dutch Kidney Foundation
First posted: 2023-06-29
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be 1:1 randomised to:

1. Continue immunosuppressive therapy with MMF/MPA
2. Replace immunosuppressive therapy with MMF/MPA by everolimus
Primary purpose: PREVENTION

Brief summary: Objective: To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior immunogenicity of COVID-19 vaccination as measured by neutralizing antibody titer against the Omicron XBB.1.5 strain.

Trial design: Multicentre, open-label randomized controlled clinical trial, for a duration of at least 10 weeks with an optional extension to 18 weeks.

Trial population: Kidney transplant recipients, 18 years or older, who are at least 6 months after transplantation, with a functioning kidney transplant, using MMF/MPA in combination with at least one other immunosuppressant including a calcineurin inhibitor (CNI), with at least 3 previous COVID-19 vaccinations (=basic COVID-19 immunisation).

Interventions:

Patients will be randomized into one of two equally sized groups, with either continuation of their current immunosuppressive regimen including MMF/MPA or replacement of MMF/MPA by everolimus during at least six weeks before until four weeks after the last vaccination. Patients will receive a repeated COVID-19 vaccination with the monovalent Omicron XBB.1.5 vaccine, 28 days thereafter they can opt to also receive two herpes zoster vaccinations with the Recombinant Zoster Vaccine (RZV) with an interval between the first and second dose of 28 days.

Main trial endpoints:

The neutralizing antibody titer against the Omicron XBB.1.5. strain 28 days after monovalent Omicron XBB.1.5 COVID-19 vaccination in patients continuing MMF/MPA compared to patients who switched to everolimus.

Secondary trial endpoints:

* SARS-CoV-2 specific anti-S1 antibody level at 28 and 56 days after COVID-19 vaccination
* Varicella zoster specific anti-gE antibody level 28 days after 1st and 2nd herpes zoster vaccination
* SARS-CoV-2 specific T-cell response 28 days after COVID-19 vaccination
* Varicella zoster specific T-cell response 28 days after 2nd herpes zoster vaccination
* Safety in terms of incidence of acute rejection, kidney function decline, SAEs, AESIs and solicited local and systemic AEs after COVID-19 and herpes zoster vaccination

Detailed description: Rationale: The immunogenicity after vaccination against SARS-CoV-2 and other pathogens is diminished in kidney transplant recipients. This patient group therefore remains extremely vulnerable for viral infections despite vaccination. This impaired immune response is related to the use of immunosuppressive agents, especially Mycophenolate Mofetil/Mycophenolic Acid (MMF/MPA). Patients that use everolimus instead of MMF/MPA elicit a higher immune response after vaccination.

Objective

Primary objective:

To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior immunogenicity of COVID-19 vaccination as measured by neutralizing antibody titer against the Omicron XBB.1.5 strain.

Secondary objectives:

* To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior humoral immunogenicity of

  * COVID-19 vaccination as measured by SARS-CoV-2 specific anti-S1 antibody levels
  * herpes zoster vaccination as measured by varicella zoster specific anti-gE antibody levels
* To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior cellular immunogenicity of

  * COVID-19 vaccination as measured by SARS-CoV-2 specific T-cell response
  * herpes zoster vaccination as measured by varicella zoster specific T-cell response
* To evaluate safety of replacement of MMF/MPA by everolimus in terms of

  * incidence of treated acute rejection, kidney function decline, incidence of serious adverse events (SAEs)
  * incidence of adverse events of special interest (AESI) of immunosuppression
  * incidence of solicited adverse events (AEs) of COVID-19 vaccination
  * incidence of solicited AEs of herpes zoster vaccination

This is a multicentre, open-label, controlled, randomized study to evaluate replacement of MMF/MPA by everolimus in KTR on immunogenicity and safety after vaccination.

The seven participating study sites are Amsterdam UMC, Erasmus MC, Leiden UMC, Maastricht UMC+, Radboudumc, UMC Groningen and UMC Utrecht.

At the first study visit, eligibility for study participation will be checked, blood will be drawn, and participants will subsequently be 1:1 randomised to:

1. Continue immunosuppressive therapy with MMF/MPA
2. Replace immunosuppressive therapy with MMF/MPA by everolimus

After randomisation, the study will continue in 2 parts:

Part 1 - Run-in and COVID-19 vaccination (≥6 weeks + 28 days) The aim of this phase is to first ensure complete washout of MMF/MPA and attaining optimal trough levels of everolimus in patients randomized to everolimus.

To monitor tolerability, safety and trough levels, participants will be invited at week 1 and week 3 after randomisation for a blood withdrawal and spot urine collection.

At least 6 weeks after randomisation, patients will receive the COVID-19 vaccination (=baseline visit). After 28 days patients will be invited for a study visit for blood withdrawal.

Part 2 (optional) - Herpes zoster vaccination (+56 days) Patients that opted to participate in this part of the study will continue their randomised treatment for the next 56 days. During this period patients will receive 2 herpes zoster vaccinations with an interval of 28 days between each vaccination. At 28 days after the second vaccination patients will be invited for the last study visit for blood withdrawal.

After completion of the study (either 28 days after COVID-19 vaccination or 28 days after the last herpes zoster vaccination) patients will be offered the option to continue everolimus instead of MMF/MPA as part of shared clinical decision making.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* ≥6 months after kidney transplantation
* Maintenance immunosuppressive therapy consisting of either triple or dual therapy including MMF/MPA with a minimum daily dose of 1000 mg (MMF) or 720 mg (MPA) and a CNI
* Eligible for the vaccinations as described by the instructions of the manufacturers of the vaccines (e.g. received 3 previous COVID-19 vaccinations as part of the primary COVID-19 immunisation)
* Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained)
* Willing to adhere to the protocol and be available during the study period

Exclusion Criteria:

* Previous CNI trough levels not sufficient according to the discretion of the treating physician
* More than two previous kidney transplantations
* Calculated level of panel reactive antibodies prior to last transplantation above 85%
* Evidence of DSAs
* Signs of acute rejection during the preceding year
* Multi-organ transplant recipient
* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s)
* Contra-indications for use of everolimus according to the opinion of the treating physician
* Active COVID-19 disease
* Active malignancy, except non-melanoma skin cancer
* Inherited immune deficiency
* Infection with Human Immunodeficiency Virus (HIV)
* Administration of T-cell, B-cell, or plasma cell depleting antibodies during the last 6 months
* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
* Subjects with severe systemic infections, current or within the two weeks prior to randomisation
* Subjects with severe restrictive or obstructive pulmonary disorders
* Subjects with severe hypercholesterolemia or hypertriglyceridemia that cannot be controlled
* Subjects with white blood cell (WBC) count ≤ 2,000/mm3 or with platelet count ≤ 50,000/mm3 at last outpatient clinic visit
* Proteinuria \> 1 gram/day at last outpatient clinic visit
* Simultaneous participation in another interventional study that will likely influence the study outcomes
* Subject who are actively trying to get pregnant or are pregnant

Additional exclusion criteria for Part 2:

* Active varicella or herpes zoster disease
* Herpes zoster vaccination with the live attenuated vaccine (Zostavax) or varicella vaccination (Provarivax) during the conduct of the study
* Previous herpes zoster vaccination with the RZV

Primary outcomes:
measure: Virus-neutralizing capacity of SARS-CoV-2 antibodies
timeFrame: 28 days after COVID-19 vaccination
Secondary outcomes:
measure: SARS-CoV-2 antibody concentration
timeFrame: 28 days after COVID-19 vaccination
measure: SARS-CoV-2 specific T-cell response
timeFrame: 28 days after COVID-19 vaccination
measure: Varicella Zoster specific antibodies
timeFrame: 28 days after second Varicella Zoster vaccination
measure: Varicella Zoster specific T-cell Response
timeFrame: 28 days after second Varicella Zoster vaccination
measure: Solicited local and systemic adverse events
timeFrame: Within 7 days after vaccination
measure: Serious adverse events
timeFrame: Within 84 days after COVID-19 vaccination
measure: Safety of kidney transplant
timeFrame: From enrollment to 84 days after COVID-19 vaccination
Other outcomes:
measure: Relationship between previous COVID-19 infection and immune responses
timeFrame: 28 days after vaccination
measure: Virus neutralizing capacity of SARS-CoV-2 antibodies
timeFrame: 28 days after COVID-19 vaccination
measure: Delayed SARS-CoV-2 antibody response
timeFrame: 56 days after COVID-19 vaccination
measure: Relationship between baseline clinical features and immune responses
timeFrame: 28 days after vaccination
Locations:
city: Nijmegen
country: Netherlands
facility: Radboud University Medical Center
state: Gelderland
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Center
state: Limburg
city: Amsterdam
country: Netherlands
facility: Amsterdam University Medical Center
state: Noord-Holland
city: Leiden
country: Netherlands
facility: Leiden University Medical Center
state: Zuid-Holland
city: Rotterdam
country: Netherlands
facility: Erasmus Medical Center
state: Zuid-Holland
city: Groningen
country: Netherlands
facility: University Medical Center Groningen
city: Utrecht
country: Netherlands
facility: University Medical Center Utrecht
Study officials:
affiliation: University Medical Center Groningen
name: Jan-Stephan F Sanders, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: